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1. Introduction and purpose 
New psychoactive substances can cause serious cross-border threats to health. A three-step legal 
framework of early warning, risk assessment and control measures allows the European Union to 
rapidly detect, assess and respond to the public health and social threats caused by new psychoactive 
substances. The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is responsible 
for the first two steps in this framework, namely operating the EU Early Warning System on new 
psychoactive substances (EMCDDA, 2019), in close cooperation with Europol, and conducting risk 
assessments. The European Commission is responsible for proposing control measures. 
On 23 November 2018, legislation came into effect that strengthened the EU’s ability to respond to the 
threats posed by new psychoactive substances (1,2). This is the third such legal framework to be 
introduced over the past 20 years and builds on the experiences gained during this period. 
The legislation comprises: 
§ Regulation (EU) 2017/2101 of the European Parliament and of the Council of 15 November 
2017 amending Regulation (EC) No 1920/2006 (3) as regards information exchange on, and 
an early warning system and risk assessment procedure for, new psychoactive substances 
(‘the Regulation’); and 
§ Directive (EU) 2017/2103 of the European Parliament and of the Council of 15 November 
2017 amending Council Framework Decision 2004/757/JHA (4) in order to include new 
psychoactive substances in the definition of ‘drug’ and repealing Council Decision 
2005/387/JHA (‘the Framework Decision’). 
The purpose of these guidelines is to ensure compliance with the scope and requirements of 
Regulation (EC) No 1920/2006 as amended by Regulation (EU) 2017/2101 in respect to the second 
step of the framework, i.e. the risk assessment procedure for and reporting on new psychoactive 
substances (Article 5c), and with Council Framework Decision 2004/757/JHA as amended by Directive 
(EU) 2017/2103. The text therefore includes appropriate references to the legal framework. To 
operationalise the technical aspects of the risk assessment, the guidelines are supported by a set of 
guidance notes developed by the EMCDDA. The guidance notes will be adapted as required in order 
to reflect developments in the field of new psychoactive substances and risk assessment. 
 
(1) Regulation (EU) 2017/2101 of the European Parliament and of the Council of 15 November 2017 amending Regulation (EC) 
No 1920/2006 as regards information exchange on, and an early warning system and risk assessment procedure for, new 
psychoactive substances, OJ L 305, 21.11.2017, pp. 1-7 (https://eur-lex.europa.eu/legal-
content/EN/TXT/?uri=CELEX:32017R2101). 
(2) Directive (EU) 2017/2103 of the European Parliament and of the Council of 15 November 2017 amending Council 
Framework Decision 2004/757/JHA in order to include new psychoactive substances in the definition of ‘drug’ and repealing 
Council Decision 2005/387/JHA, OJ L 305, 21.11.2017, pp. 12-18 (https://eur-lex.europa.eu/legal-
content/en/TXT/?uri=CELEX:32017L2103). 
(3) Regulation (EC) No 1920/2006 of the European Parliament and of the Council of 12 December 2006 on the European 
Monitoring Centre for Drugs and Drug Addiction (recast). OJ L 376, 27.12.2006, pp. 1-13 (https://eur-lex.europa.eu/legal-
content/EN/TXT/?uri=CELEX:32006R19). 
(4) Council Framework Decision 2004/757/JHA of 25 October 2004 laying down minimum provisions on the constituent elements 
of criminal acts and penalties in the field of illicit drug trafficking. OJ L 335, 11.11.2004, pp. 8-11 (https://eur-lex.europa.eu/legal-
content/EN/ALL/?uri=CELEX:32004F0757).  
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The risk assessment has regard to the health and social risks of the use of, manufacture of and traffic 
in new psychoactive substances, including the involvement of criminal groups. The guidelines and 
guidance notes put in place a sound methodological and procedural basis for carrying out each risk 
assessment, ensuring that a systematic, reproducible and transparent approach is used throughout 
the risk assessment procedure. The guidelines draw from developments in the field of risk 
assessment (5), notably the use of a weight-of-evidence framework (SCHEER, 2018), as well as the 
practical experience gained by the EMCDDA and its Scientific Committee over the past 10 years. 
The guidelines replace those previously published by the EMCDDA in 2010. 
Guidance notes 
§ Guidance note 1: terminology and definitions. 
§ Guidance note 2: EMCDDA technical report. 
§ Guidance note 3: weight-of-evidence framework. 
§ Guidance note 4: analysing and assessing epidemiological data. 
§ Guidance note 5: analysing and assessing law enforcement seizure data. 
§ Guidance note 6: analysing and assessing serious adverse events. 
§ Guidance note 7: analysing and assessing social harms. 
2. Legal basis and scope 
The legal basis for the risk assessment of new psychoactive substances is provided in Regulation 
(EC) No 1920/2006 as amended by Regulation (EU) 2017/2101 and in Framework Decision 
2004/757/JHA as amended by Directive (EU) 2017/2103. 
Regulation (EC) No 1920/2006 (as amended) has regard to the Treaty establishing the European 
Community (TEC) (6), and in particular Article 152 thereof, and the Treaty on the Functioning of the 
European Union (TFEU) (7), and in particular Article 168(5) thereof. Article 168(1) of the TFEU 
provides that drugs-related health damage is considered a public health issue of concern for the EU. 
The Framework Decision in its turn has regard to the Treaty on European Union (TEU) (8), in particular 
Article 31(e) and Article 34(2)(b) thereof, and the TFEU, in particular Article 83(1) thereof. These 
articles concern judicial cooperation in criminal matters between Member States of the European 
Union. Article 83(1) of the TFEU provides that illicit drug trafficking is considered a particularly serious 
crime with a cross-border dimension, motivating judicial cooperation in criminal matters within the EU. 
 
(5) This includes drawing from relevant advances in assessment methodologies of substances in a broader sense, especially 
within EU institutions and bodies. Consequently, the conceptual framework for the risk assessment has been adapted. Notably, 
a weight-of-evidence framework that includes an uncertainty analysis has been integrated into the risk assessment. 
(6) OJ C 325, 24.12.2002. 
(7) OJ C 326, 26.10.2012. 
(8) OJ C 326, 26.10.2012. 
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The Framework Decision provides for a common approach to tackle illicit drug trafficking, which poses 
a threat to the health, safety and quality of life of citizens of the Union, to the legal economy and to the 
stability and security of the Member States. 
The Framework Decision was amended by Directive (EU) 2017/2103 in order to include new 
psychoactive substances in the definition of ‘drug’ and repealed Council Decision 2005/387/JHA. 
Simultaneously, the Regulation was amended by Regulation (EU) 2017/2101. Together, the 
Regulation and the Framework Decision replace the mechanism established by Council Decision 
2005/387/JHA (9). 
Article 1(4) of the Framework Decision defines a ‘new psychoactive substance’ as a substance in pure 
form or in a preparation that is not covered by the 1961 United Nations Single Convention on Narcotic 
Drugs, as amended by the 1972 Protocol, or by the 1971 United Nations Convention on Psychotropic 
Substances (10), but may pose health or social risks similar to those posed by the substances covered 
by those conventions. 
Article 1(1) of the Framework Decision defines a ‘drug’ as a substance covered by the 1961 United 
Nations Single Convention on Narcotic Drugs, as amended by the 1972 Protocol, or by the 1971 
United Nations Convention on Psychotropic Substances; and any of the substances listed in the 
Annex to the Framework Decision. The substances listed in the Annex are those psychoactive 
substances that are already subject to control measures adopted in accordance with Joint Action 
97/396/JHA (11) and Decision 2005/387/JHA, and those substances that will be subjected to control 
measures by delegated acts adopted in accordance with the Framework Decision, based on a risk 
assessment or combined risk assessments carried out pursuant to Article 5c of the Regulation. 
Thus, while the Regulation focuses on public health, the Framework Decision concerns judicial 
cooperation in criminal matters. Both pieces of legislation work together. The Regulation has been 
designed to ensure a high level of human health protection and to complement the Member States’ 
actions in reducing drugs-related health damage, including exchange of information and prevention, 
more specifically where this concerns new psychoactive substances, which can pose serious cross-
border threats to health. The Framework Decision has been designed to support a common approach 
and provides for procedures to include new psychoactive substances within the definition of ‘drug’, 
thereby extending the application of the Union criminal law provisions that apply to illicit drug 
trafficking to new psychoactive substances posing severe public health risks and, where applicable, 
severe social risks. This approach also strengthens law enforcement and judicial cooperation across 
the Union after a new psychoactive substance is brought under the definition of a ‘drug’. 
The scope of the risk assessment is limited to new psychoactive substances, meaning that the 
substances may pose health or social risks similar to those posed by the substances covered by 
United Nations 1961 (as amended by the 1972 Protocol) and 1971 international drug control 
conventions. Whether or not a substance is considered a new psychoactive substance is based on an 
 
(9) OJ L 127, 20.5.2005. 
(10) UNODC (United Nations Office on Drugs and Crime) (2013), The international drug control conventions, UNODC, Vienna 
(https://www.unodc.org/documents/commissions/CND/Int_Drug_Control_Conventions/Ebook/The_International_Drug_Control_
Conventions_E.pdf). 
(11) OJ L 167, 25.6.1997. 
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assessment by the EMCDDA of the available information reported through the Early Warning System 
in accordance with Article 2(f)(i) and Article 5a of the Regulation (EMCDDA, 2019). 
The request for a risk assessment is made by the European Commission in accordance with 
Article 5c(1) and Article 5d, based on the initial report prepared by the EMCDDA in accordance with 
Article 2(f)(ii) and Article 5b of the Regulation (EMCDDA, 2019). The risk assessment procedure is 
organised by the EMCDDA in accordance with Article 2(f)(iii) and Article 5c(5) of the Regulation. 
If the EMCDDA has collected information on several new psychoactive substances that it considers of 
similar chemical structure and if each of them gives rise to concerns that it may pose health or social 
risks at Union level, the EMCDDA shall in accordance with Article 5b(11) of the Regulation submit to 
the Commission and to the Member States individual initial reports or combined initial reports dealing 
with several new psychoactive substances. When a combined initial report is submitted, the 
Commission may request the EMCDDA to assess the potential risks posed by several new 
psychoactive substances with similar chemical structures and to draw up a combined risk assessment 
report. 
The risks posed by the new psychoactive substance are assessed by the Scientific Committee of the 
EMCDDA, which may be extended as deemed necessary, in accordance with Article 5c(4) and 
Article 13(2) of the Regulation. The Scientific Committee shall assess the risks on the basis of the 
available information and any other relevant scientific evidence, in accordance with Article 5c(5) of the 
Regulation. It shall take into account all opinions held by its members. 
3. Conceptual framework for risk assessment 
Based on the experience gained with risk assessments of new psychoactive substances and 
consistent with advances in methodologies used for the risk assessment of substances in areas such 
as food safety, chemicals, consumer products and medicines, a weight-of-evidence approach is 
considered appropriate for assessing the risks posed by new psychoactive substances. In line with the 
definition provided by the European Commission’s Scientific Committee on Health, Environmental and 
Emerging Risks (SCHEER) (12,13), a weight-of-evidence approach is ‘a process of weighted integration 
of lines of evidence to determine the relative support for hypotheses or answers to a question’. To 
reach valid conclusions or answers to questions, a structured methodology needs to be followed, 
containing the elements of: 
§ a problem statement; 
§ the identification, collection and selection of possible sources of evidence; 
§ an assessment and weighing of individual lines of evidence and integration of lines of 
evidence; and 
§ an uncertainty analysis (description of uncertainties) 
 
(12) https://ec.europa.eu/health/scientific_committees/scheer_en  
(13) SCHEER (Scientific Committee on Health, Environmental and Emerging Risks) (2018), Memorandum on weight of evidence 
and uncertainties — revision 2018, European Commission 
(https://ec.europa.eu/health/sites/health/files/scientific_committees/scheer/docs/scheer_o_014.pdf). 
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Detailed information on the weight-of-evidence framework for use in the risk assessment of new 
psychoactive substances is provided in Guidance Note 3. 
3.1. Problem statement 
The problem statement for the risk assessment of a new psychoactive substance is the request from 
the European Commission to the EMCDDA to perform a risk assessment of a new psychoactive 
substance or several new psychoactive substances with similar chemical structures. The request is 
based on indications in the initial report to suggest that the substance may pose severe public health 
risks and, where applicable, severe social risks at Union level. Based on the risk assessment by the 
Scientific Committee of the EMCDDA, the Commission needs to consider whether to adopt a 
delegated act, in accordance with the Framework Decision, which would add the new psychoactive 
substance to the Annex of the Framework Decision. For this, the Commission has to take into account 
whether the new psychoactive substance can be included in the definition of a ‘drug’. Article 1a(2) of 
the Framework Decision provides the elements that need to be considered by the Commission. 
Consequently, the risk assessment performed by the Scientific Committee of the EMCDDA should 
provide the relevant information on these elements. Thus, by default, the problem statement can be 
derived from the legislation and summarised by three questions: 
1. Are the extent or patterns of use of the new psychoactive substance and its availability and 
potential for diffusion within the Union significant? 
2. Is the harm to health caused by the consumption of the new psychoactive substance, associated 
with its acute or chronic toxicity and abuse liability or dependence-producing potential, life 
threatening? 
3. Is the social harm caused by the new psychoactive substance to individuals and to society 
severe? 
The Framework Decision provides additional details on these questions. These will be further 
discussed in Section 5. 
3.2. Identification, collection and selection of possible sources of evidence 
The identification, collection and selection of possible sources of evidence begins before the request 
for a risk assessment is made. Important sources are the EMCDDA’s Reitox national focal points and 
Europol national units, who collect and report information as part of the Early Warning System in 
accordance with Article 5a of the Regulation. Together with other sources of information, including 
available information in the literature, this information is added to the initial report on the basis of which 
a risk assessment is requested (Article 5b). Subsequently, the available information is compiled and 
analysed in a technical report prepared by the EMCDDA in order to support the risk assessment. To 
support the uncertainty analysis (Section 3.4), the technical report should also qualify the available 
information. Details on the structure and information included in the EMCDDA technical report are 
provided in Guidance Note 2. 
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3.3. Assessment and weighing of individual lines of evidence and integration of 
lines of evidence 
The next step in the risk assessment is that in which the lines of evidence are assessed, weighed and 
integrated. The use of a weight-of-evidence approach means that each piece of evidence is taken as 
part of a line of evidence. It should be considered to what extent each line of evidence is supported by 
evidence and what the strength of that evidence is. Where different lines of evidence exist, it should 
be considered to what extent these lines of evidence are congruent or whether there are conflicts 
between the lines of evidence. Together, this weight-of-evidence approach should determine the 
relative support for hypotheses or answers to the questions posed in the problem statement. It is 
important to note that, because of the typically short period of time between a new psychoactive 
substance emerging on the market and the need for a risk assessment arising, the extent of data 
available will often be limited and the available data will vary in quality (Section 4.3). 
3.4. Uncertainty analysis 
In the uncertainty analysis, uncertainty is used as a general term referring to all types of limitations in 
available knowledge that affect the range and probability of possible answers to an assessment 
question. Uncertainty is due to lack of knowledge regarding the true value of a quantity, and is also 
termed epistemic uncertainty, lack-of-knowledge uncertainty or subjective uncertainty. Uncertainty 
analysis is an integral part of the risk assessment, rather than a separate phase. Yet by specifically 
addressing uncertainty analysis, the existing uncertainties can be made explicit. 
Uncertainty analysis begins by weighing the strength of the evidence. The strength of the evidence is 
affected by various factors. 
§ First, the reliability of the pieces of evidence need to be considered. The qualification of the 
evidence is provided in the technical report, as this qualification is an elementary part of the 
risk assessment. It is a task of the EMCDDA Scientific Committee to agree or disagree with 
qualifications provided in the technical report. In this respect, Article 5c(5) of the Regulation 
establishes that the risk assessment shall take into account all opinions held by the 
members of the Scientific Committee. 
§ Another factor determining the level of uncertainty is the existence of knowledge gaps, 
limiting the ability to assess appropriately the risks. Where data are available but the extent 
is limited, the precision of an answer given would be affected. The more data available, the 
more precise the answer can be. 
§ Finally, the accuracy of the available data will be affected by the methods that were used to 
gather or generate these data. The cruder the methods are, the greater is the chance that 
the data are less accurate. When the data are less accurate, the answer to the questions 
will also be less accurate. 
In addition to uncertainties stemming from limitations in the data, uncertainty also depends on the risk 
assessment methodologies used. In view of the paucity of data and the limited time available for the 
risk assessment of new psychoactive substances, the principal method used is expert judgement. This 
method relies on the knowledge and experience of the experts involved. It is the responsibility of the 
EMCDDA to organise the risk assessment so as to minimise bias where risk assessment depends on 
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expert judgement. In this respect, Article 5c(4) of the Regulation allows for the Scientific Committee to 
be extended as deemed necessary by the Director, acting on the advice of the chairperson of the 
Scientific Committee, by including experts representing the scientific fields relevant for ensuring a 
balanced assessment of the risks posed by the new psychoactive substance under assessment. 
4. General considerations for risk assessment 
When assessing the risks posed by a new psychoactive substance as required by Article 5c, the 
following general principles need to be taken into consideration. 
4.1. Risk, hazard and harm 
The risks that need to be assessed in the EU risk assessments for new psychoactive substances 
relate to public health risks and, where applicable, social risks, including those related to criminal 
activities. Risk assessment methodologies have advanced in health sciences, where the dual 
functionality of risk is firmly established: both the likelihood of a harmful health effect occurring and the 
severity of that effect are taken into account. To extend this methodology to the risk assessment of 
new psychoactive substances, a broadened definition of risk is used to include both harmful health 
effects and social harms: risk is taken as a combination of the likelihood of occurrence of a hazard 
generating harm in a given scenario and the severity of that harm. 
Within the context of an EU risk assessment for new psychoactive substances, harm is taken as injury 
or damage to the health of people or disruption of social functioning or public order resulting in injury 
or damage to the health of the user or other persons, damage to property or criminal activities as 
described in the procedure for including new psychoactive substances in the definition of ‘drug’. Risk 
should not be confused with hazard, which is something that has a potential to cause harm. 
Both the likelihood of harm and the severity of harm should be assessed and, to the extent possible, 
quantified. Verbal expressions expressing the likelihood or the severity of a risk can be used. 
However, it should be made explicit what is meant by words such as ‘rare’, ‘low’, ‘moderate’, ‘high’ and 
‘serious’. The comparison of the substance under assessment with the similar substances scheduled 
under the UN conventions is included in the technical report. 
To express the overall magnitude of a risk, i.e. the risk level, both likelihood and severity may be 
expressed in a risk matrix, where both an increased likelihood of harm occurring and the increased 
severity of the harm would increase the risk level. The use of risk matrices (Guidance Note 3) should 
be considered supportive in the risk assessment and serves to provide consistent and objective and 
transparent assessments. 
4.2. Risk-modifying factors 
The risks posed by new psychoactive substances are not a simple function of the pharmacological or 
toxicological properties of the substance. The physical, social, cultural, economic and political 
environment as well as user-related elements affect the likelihood that harm will actually occur and the 
severity and outcome of the harm. Therefore, these factors can be seen as risk-modifying factors. 
Modalities of substance use may include patterns of use (including routes of administration, dosage 
forms, dosage regimens) and the context of use. Concerning the social environment, regulatory 
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policies, informal norms, criminal involvement, living standards (poverty), the availability of information 
and peer support can affect the likelihood of harm. Individual vulnerabilities and personal 
circumstances such as age, gender, genetics, pre-existing medical conditions, personality, education 
and employment are examples of individual user characteristics affecting the likelihood of harm. 
4.3. Availability and quality of data 
Because of the typically short period of time between a new psychoactive substance emerging on the 
market and the need for a risk assessment arising, the extent of the data available will often be limited 
and the available data will vary in quality. Whereas forensic reports of law enforcement seizures or 
toxicology reports related to serious adverse events, such as acute poisonings and deaths, may 
contain high-quality data, surveys investigating the use of new psychoactive substances are often 
lacking or limited to non-representative targeted surveys. To deal with these limitations, the data that 
are considered in a risk assessment need to be assessed for reliability and relevance (Guidance Note 
3). This information on the quality of data should be included in the technical report. 
Gaps in information can lead to the conclusion that some questions cannot be answered. Yet 
sometimes answers can be inferred from existing knowledge on other substances. For instance, µ-
opioid receptor agonists display a well-described general pharmacological and toxicological profile. 
This makes it possible to assign class-related behavioural or toxicological effects to a novel µ-opioid 
receptor agonist, based on this pharmacological property, provided that other information is available 
demonstrating that the substance is effectively reaching the central µ-opioid receptors. On the other 
hand, substances with pharmacological profiles that are less well defined may be less amenable to 
this type of extrapolation. Extrapolation based on chemical similarity can be done only with great 
caution and would normally require a group of comparators with similar chemical and pharmacological 
characteristics. Extrapolation of risks based on a single analogue would rarely suffice. 
Both the quality of the information and the gaps in information will affect the level of uncertainty in the 
answers to the questions posed. To deal with the limitations of information in a scientifically sound 
manner, uncertainty needs to be made explicit in the conclusions of the risk assessment (Section 3.4; 
Guidance Note 3). 
5. Risk assessment report 
According to Article 5c of the Regulation, following the assessment of the potential risks of a new 
psychoactive substance by the Scientific Committee, it should draw up a risk assessment report (14) 
that contains: 
§ available information on the chemical and physical properties of the new psychoactive 
substance and the methods and the precursors used for its manufacture or extraction; 
§ available information on the pharmacological and toxicological properties of the new 
psychoactive substance; 
 
(14) Or draw up a combined risk assessment report in the case of the assessment of several new psychoactive substances with 
similar chemical structures in accordance with Article 5c(2) of the Regulation. 
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§ an analysis of the health risks associated with the new psychoactive substance, in particular 
with respect to its acute and chronic toxicity, abuse liability, dependence-producing potential 
and physical, mental and behavioural effects; 
§ an analysis of the social risks associated with the new psychoactive substance, in particular 
its impact on social functioning, public order and criminal activities, and the involvement of 
criminal groups in the manufacture, distribution and distribution methods, and trafficking of 
the new psychoactive substance; 
§ available information on the extent and patterns of use of the new psychoactive substance, 
its availability and potential for diffusion within the Union; 
§ available information on the commercial and industrial use of the new psychoactive 
substance, the extent of such use, as well as its use for scientific research and development 
purposes; and 
§ other relevant information, where available. 
The headings given below reflect those required for the risk assessment report by Article 5c(3) of the 
Regulation. 
5.1. Problem statement 
By default, the problem statement is aligned with three questions as required by Article 1a(2) of the 
Framework Decision (Section 3.1): 
§ Are the extent or patterns of use of the new psychoactive substance and its availability and 
potential for diffusion within the Union significant? 
§ Is the harm to health caused by the consumption of the new psychoactive substance, 
associated with its acute or chronic toxicity and abuse liability or dependence-producing 
potential, life threatening? 
§ Is the social harm caused by the new psychoactive substance to individuals and to society 
severe? 
5.2. Description of the substance 
The description of the substance(s) should be a summary extracted from the technical report. The 
description should be precise to avoid any ambiguity about the actual substances assessed. 
5.2.1. Chemical and physical properties 
In accordance with Article 5c(3)(a) of the Regulation, the report should contain the available 
information on the chemical and physical properties of the new psychoactive substance. 
Information on the following should be included: the names of the substance, and the chemical 
structure, molecular formula and molecular weight of the substance and its physico-chemical 
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properties; the chemical similarity of the substance to substances scheduled under the UN 
conventions; and relevant considerations related to the analytical identification of the substance. 
5.2.2. Methods and the precursors used for the manufacture or extraction 
In accordance with Article 5c(3)(a) of the Regulation, the report should contain the available 
information on the methods and the precursors used for the manufacture or extraction of the new 
psychoactive substance. Such information may come from analyses of chemicals found at production 
sites or from the literature. The description should include the most likely routes of synthesis as well as 
impurities/side products of synthesis, if known. 
5.3. Pharmacological and toxicological properties 
In accordance with Article 5c(3)(b) of the Regulation, the report should contain the available 
information on the pharmacological and toxicological properties of the new psychoactive substance. 
This would include both in vitro and in vivo data. Of great interest are data characterising the new 
psychoactive substance with respect to its receptor pharmacology. Therefore, receptor binding data 
and functional activity data are important. Data concerning receptors implicated in substance 
dependence especially need to be considered. In addition, for a better understanding of potential side 
effects, secondary pharmacological data are relevant as well. Data from in vivo models may further 
demonstrate the pharmacological activity of the new psychoactive substance. Regarding the function 
of vital organs (principally the heart, lungs and central nervous system), pharmacological safety data 
need to be considered. 
Usually, pharmacokinetic data on the new psychoactive substance are very limited. When available 
and where pharmacokinetic data are considered relevant for the risk assessment, these should be 
included in Section 5.3 of the report, for example distribution data showing the uptake in brain tissue 
or metabolism data showing the formation of a metabolite with relevant activity at receptors implicated 
in substance dependence. 
In vitro and animal data demonstrating the toxicological properties are considered relevant for 
characterising the new psychoactive substance. Usually, human toxicological data are limited to case 
reports on serious adverse events such as acute poisonings and medico-legal death investigations. 
These data should be included in Section 5.6. 
5.4. Legitimate use and other relevant information 
In accordance with Article 5c(3)(g) of the Regulation, the report should contain the available 
information on the commercial and industrial use of the new psychoactive substance, the extent of 
such use, as well as its use for scientific research and development purposes. This information will be 
collected during the preparation of the initial report and should be included in this section. 
In accordance with Article 5c(3)(h) of the Regulation, the report may contain other relevant 
information, which can also be included in this section. 
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5.5. Extent and patterns of use, availability and potential for diffusion within the 
Union 
In accordance with Article 5c(3)(e) of the Regulation, the report should contain the available 
information on the extent and patterns of use of the new psychoactive substance, and its availability 
and potential for diffusion within the Union. This information is derived from the EMCDDA technical 
report (Guidance Note 2). The risk assessment should provide the information relevant for answering 
the question of whether the extent or patterns of use of the new psychoactive substance and its 
availability and potential for diffusion within the Union are significant. 
Following the weight-of-evidence approach, the key data should be presented as evidence and the 
strength of the evidence should be evaluated, thus weighing the evidence and showing how the 
evidence contributes to the conclusions reached (Guidance Note 3). Concerning the extent of use, 
formal epidemiological data would be considered to have a greater weight than for example survey 
data from an internet forum, as, in the latter case, biases are likely to be greater. Detailed information 
on analysing and assessing epidemiological data is provided in Guidance Note 4. 
As information on the extent and patterns of use of the new psychoactive substance and its availability 
and potential for diffusion within the Union is likely to be very limited at the time of risk assessment, 
information will be based largely on information from case reports of seizures reported by law 
enforcement agencies, including information on frequencies and circumstances of seizures, and the 
quantities of the new psychoactive substance seized. Guidance Note 5 provides detailed information 
on the analysis and assessment of such data relevant for the risk assessment of new psychoactive 
substances. Data from online vendors of new psychoactive substances may also provide relevant 
information. 
In addition to an estimate on the current use and availability (if possible, considering the limited data), 
the anticipated trends in use and availability would also be considered relevant for inclusion in a risk 
assessment report. 
5.6. Health risks 
In accordance with Article 5c(c) of the Regulation, the health risks associated with the new 
psychoactive substance should be analysed with respect to its acute and chronic toxicity, physical, 
mental and behavioural effects, and abuse liability and dependence potential (Section 5.7). 
The Commission needs to take into account whether the harm to health caused by the consumption of 
the new psychoactive substance is life threatening. Following from Article 1a(2) of the Framework 
Decision, the risk assessment report needs to provide information enabling the Commission to take 
into account whether the new psychoactive substance: 
§ is likely to cause death or lethal injury; 
§ is likely to cause severe disease; 
§ is likely to cause severe physical or mental impairment; 
§ is likely to cause a significant spread of diseases, including the transmission of blood-borne 
viruses. 
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In addition to animal toxicity data, which have been discussed in Section 5.3, acute toxicity data are 
mainly based on forensic reports describing cases of serious adverse events, such as acute 
poisonings and medico-legal death investigations. Guidance Note 6 provides detailed information on 
the analysis and assessment of serious diverse events relevant for the risk assessment of new 
psychoactive substances. This may concern both reports through the Early Warning System from the 
Member States, as well as reports published in the medical and scientific literature. 
For a full appreciation of the severity and seriousness of the effects, a detailed description from 
reliable sources would be required. 
To evaluate the association of the use of the new psychoactive substance with harmful health effects, 
toxicological data from body fluids or tissues demonstrating the actual intake of the new psychoactive 
substance would provide the strongest evidence (Guidance Note 6). An analysis of dosage forms 
present at the scene could further support the association. Self-reported information from users on the 
other hand is evidence with a high level of uncertainty, as the actual contents of the substances taken 
may differ from what the user may believe or claim to have taken. As in many cases several 
substances may have been consumed, the contribution of the new psychoactive substance under 
evaluation or its metabolites to causing the harmful health effect needs to be assessed. A review of 
case reports by forensic experts would support this assessment. 
Data on the physical, mental and behavioural effects may rarely come from studies in a controlled 
setting. Other data may come from surveys among users or from users self-reporting on internet 
forums. The level of uncertainty associated with self-reporting would be high. 
The likelihood of harmful health effects occurring is not merely a function of the pharmacological and 
toxicological properties of the new psychoactive substance. In a risk assessment, all known risk-
modifying factors increasing or decreasing the likelihood of harmful health effects need to be 
considered (Section 4.2; Guidance Note 6). 
The uncontrolled preparation of dosage forms can also lead to high variability in the concentration of 
the new psychoactive substance in the final preparation. This poses a potential risk of overdosing, 
especially with new psychoactive substances with high pharmacological potency. For instance, a 
mixture of synthetic cannabinoids with herbal preparations may result in a large variability in 
cannabinoid content, which increases the risk of overdosing. 
The purity and presence of side products depend on the route of synthesis and the capabilities of the 
manufacturer (Section 5.2.2). The conditions under which new psychoactive substances are produced 
may vary from reasonably controlled for new psychoactive substances that are still not subject to 
control measures to very poor when they are synthesised in locations run by criminal organisations or 
other locations where they are manufactured non-professionally. Larger variability in purity and higher 
levels of side products would increase the likelihood of harmful health effects. 
Oral dosage forms may be associated with increases in time of onset of effects due to slow 
pharmacokinetics and/or dissolution profiles. Such a delay may cause the user, assuming the dose 
taken was too low, to take additional doses, again leading to an increased risk of overdosing. 
A specific risk associated with injectable dosage forms (e.g. intravenous, intramuscular or 
subcutaneous routes) or insufflation is the transmission of blood-borne viruses. 
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New psychoactive substances, having a propensity to allow the development of tolerance, may lead to 
an increase in the dose needed for the sought effect if the new psychoactive substance is consumed 
regularly. This same dose could in a person not or no longer tolerant to the new psychoactive 
substance lead to an overdose. 
Other user-related characteristics such as age and experience with the use of drugs in general may 
also affect the likelihood of harmful health effects. 
Increasing the availability of information among users, through internet forums, educational material or 
otherwise, could help to reduce the likelihood of harmful health effects, as it may encourage users to 
use more appropriate procedures for consuming the new psychoactive substance. 
The context and circumstances of use also affect the likelihood of harmful health effects. For instance, 
taking new psychoactive substances alone at home poses the risk that no one is around to intervene 
should an overdose occur. The presence and availability of antidotes to users, friends or relatives, or 
first-response personnel may decrease the likelihood of fatalities due to overdoses, an issue that has 
been shown to be relevant for opioids. Co-administration of other substances (polydrug use), including 
alcohol and medicines, may lead to interactions, which could increase the likelihood of harmful health 
effects. Other circumstances such as continuous dancing in a hot environment may increase the 
likelihood of pharmacologically triggered hyperthermia. 
Information on the effects of the new psychoactive substance on the ability to drive and operate 
machinery, although rarely available at the time of risk assessment, should be included if possible. 
The legal status of a new psychoactive substance may also affect the likelihood of harmful health 
effects. In places where the new psychoactive substance is an illicit drug, the user will obtain the 
product through illicit routes, affecting the risks in various ways, as described. Use of an illicit product 
may also diminish the likelihood that a user will admit to using it, which can delay proper treatment in 
healthcare facilities when needed. 
5.6.1 Elements to consider for assessing health risks 
§ Acute toxicity, including safety profile and information on poisonings. 
§ Chronic toxicity, including functional brain damage, reproductive toxicity, genotoxicity and 
carcinogenic potential. 
§ Abuse liability and dependence-producing potential (physical and psychological). 
§ Psychosocial dysfunction. 
§ Similarities to and differences from other reference substances. 
§ Extent, frequency and patterns of use. 
§ Availability and quality of the new psychoactive substance on the market (purity, 
adulterants, etc.). 
§ Availability of information, degree of knowledge and perceptions among users concerning 
the psychoactive substance and its effects. 
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§ Characteristics and behaviour of users (including risk factors, vulnerability, etc.). 
§ Nature and extent of health consequences (e.g. acute poisonings, chronic poisonings, road 
traffic accidents). 
§ Long-term consequences of use (e.g. irreversible toxicity leading to deterioration of health 
at later stages of life). 
§ Conditions under which the new psychoactive substance is obtained and used, including 
context-related effects and risks (e.g. continuous dancing in hot environments, other 
substances used). 
5.7. Abuse liability and dependence potential 
In accordance with Article 5c(c) of the Regulation, the health risks associated with the new 
psychoactive substance should be analysed with respect to abuse liability and dependence-producing 
potential. 
In the context of a risk assessment of a new psychoactive substance and in line with the definition 
provided by the World Health Organization (WHO) Expert Committee on Drug Dependence (ECDD) 
and similar to the ICD-10 definition (15) of substance dependence syndrome, dependence-producing 
potential is the propensity of a new psychoactive substance to lead to a cluster of physiological, 
behavioural and cognitive phenomena of variable intensity, in which the use of a new psychoactive 
substance takes on a high priority. The necessary descriptive characteristics are preoccupation with a 
desire to obtain and take the drug and persistent drug-seeking behaviour. Determinants and the 
problematic consequences of drug dependence may be biological, psychological or social, and usually 
interact. 
The term ‘abuse liability’ is sometimes used interchangeably with ‘dependence-producing potential’, 
but sometimes these terms are given separate definitions. The WHO Lexicon of Alcohol and Drug 
Terms (16) defines abuse liability as the propensity of a particular psychoactive substance to be 
susceptible to abuse, defined in terms of the relative probability that use of the substance will result in 
social, psychological or physical problems for an individual or for society. The term ‘abuse liability’ puts 
more emphasis on the harmful consequences of use. Even if the use of a new psychoactive 
substance lacks specific characteristics of dependence, such as preoccupation with a desire to obtain 
and take the drug and persistent drug-seeking behaviour, the use may still have harmful effects. If a 
new psychoactive substance is used despite its harmful consequences, we could still speak of abuse 
liability. For the purpose of the risk assessment of new psychoactive substances, both terms could be 
taken together such that the relevant elements of dependence-producing potential and abuse liability 
are all assessed. 
One line of evidence comes from in vitro data showing the ability of a substance to interact with 
receptors known to be involved in substance dependence, such as µ-opioid agonists or substances 
causing increased dopaminergic transmission in the nucleus accumbens. Receptor binding or activity 
 
(15) ICD-10 is the WHO’s 10th revision of the International Statistical Classification of Diseases and Related Health Problems 
(ICD) (https://icd.who.int/browse10/2016/en). 
(16) WHO (World Health Organisation) (1994), WHO Lexicon of alcohol and drug terms 
(https://www.who.int/substance_abuse/terminology/who_ladt/en).  
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alone would not constitute sufficient evidence of dependence potential. This should rather be seen as 
a hazard. Other factors such as pharmacokinetics and dosage form would affect the likelihood that the 
new psychoactive substance indeed can induce the physiological processes leading to substance 
dependence. 
Further evidence may come from behavioural studies in animals or humans aimed at evaluating 
dependence potential. In general, the paradigms used in these studies have been shown to have a 
high level of predictivity. However, unconfirmed studies should be interpreted with caution, especially 
where unexpected results are reported. 
Social field work studies or reports from healthcare professionals may provide observations indicating 
the existence of the elementary characteristics of dependence potential such as preoccupation with a 
desire to obtain and take the drug and persistent drug-seeking behaviour. 
Poor psychosocial conditions of living could increase the likelihood that a new psychoactive substance 
will be used despite harmful consequences, whereas the occurrence of untoward side effects may 
deter others. These interdependencies should be considered when assessing the likelihood that a new 
psychoactive substance will lead to harmful use or a state of dependence. 
In addition, the attractiveness of the subjective effects of a new psychoactive substance to specific 
groups may be considered with regard to the likelihood that the new psychoactive substance may 
have abuse liability for these groups. 
5.8. Social risks 
In accordance with Article 5c(d) of the Regulation, the social risks associated with a new psychoactive 
substance should be analysed — in particular its impact on social functioning and public order, 
including disruption to public order as well as violent or anti-social behaviour, resulting in harm to the 
user or to other persons or damage to property. In addition, criminal activities and the involvement of 
criminal groups in the manufacture, distribution and distribution methods, and trafficking of the new 
psychoactive substance should also be analysed, including those related to organised crime. The 
analysis should assess whether they are systematic and provide information on the illicit profits 
involved and the economic costs related to the involvement of criminal groups. Guidance Note 7 
provides detailed information on the analysis and assessment of social harms for the risk assessment 
of new psychoactive substances. 
5.8.1 Elements to consider for assessing social risks 
§ Individual social risks (e.g. impact on education or career, problems with personal 
relationships). 
§ Possible effects on direct social environment (e.g. neglect of family, violence). 
§ Possible effects on society as a whole (public order and safety, acquisitive crime). 
§ Economic costs (demands on healthcare). 
§ Possible effects related to cultural context, for example marginalisation. 
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§ Possible appeal of the new psychoactive substance to specific population groups within the 
general population. 
§ Evidence that criminal groups are involved in production, trafficking or distribution for 
financial gain. 
§ Impact on the production, trafficking and distribution of other substances, including existing 
as well as new psychoactive substances. 
§ Evidence that the same groups or people are involved in different kinds of crime. 
§ Impact of violence from criminal groups on society as a whole or on social groups or local 
communities (public order and safety). 
§ Evidence of money-laundering practices or the impact of organised crime on other 
socioeconomic factors in society. 
§ Economic costs and consequences (evasion of taxes or duties, costs to the judicial system). 
§ Use of violence between or within criminal groups. 
§ Evidence of strategies to prevent prosecution, for example through corruption or 
intimidation. 
5.9. Risk assessment and uncertainty analysis 
In accordance with Article 5c(3)(c) of the Regulation, the report should contain an analysis of the 
health risks associated with the new psychoactive substance, in particular with respect to its acute and 
chronic toxicity, abuse liability, dependence-producing potential, and physical, mental and behavioural 
effects. Together, these sections should provide the relevant information for answering the question of 
whether the harm to health caused by the consumption of the new psychoactive substance, 
associated with its acute or chronic toxicity and abuse liability or dependence-producing potential, is 
life threatening. 
In accordance with Article 5c(3)(d) of the Regulation, the report should contain an analysis of the 
social risks associated with the new psychoactive substance — in particular its impact on social 
functioning, public order and criminal activities, and the involvement of criminal groups in the 
manufacture, distribution and distribution methods, and trafficking of the new psychoactive substance. 
This section should provide the relevant information for answering the question of whether the social 
harm caused by the new psychoactive substance to individuals and to society is severe. 
In accordance with Article 5c(3)(e) of the Regulation, the report should contain the available 
information on the extent and patterns of use of the new psychoactive substance, and its availability 
and potential for diffusion within the Union. This section should provide the relevant information for 
answering the question of whether the extent or patterns of use of the new psychoactive substance 
and its availability and potential for diffusion within the Union are significant. 
When addressing the topics in each subsection below, the weight-of-evidence approach as described 
in the chapter on the conceptual framework in these guidelines should be followed, as well as 
Guidance Note 3. Both the likelihood and the severity of the consequences should be weighed. The 
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relevant evidence should be summarised and it should be shown how this evidence contributes to the 
lines of evidence supporting possible answers to the questions posed. In addition, the existing 
uncertainties should be identified and their impact on the range of possible answers should be 
discussed. 
5.10. Conclusion 
In this section, the questions formulated in the problem statement (Section 5.1) should be answered. 
This requires: 
§ a summary description of the extent and pattens of use of the new psychoactive substance 
and its availability and potential for diffusion within the Union, along with an indication of 
whether these are considered significant; 
§ a summary description of the main harms to health caused by the consumption of the new 
psychoactive substance, associated with its acute or chronic and abuse liability and 
dependence-producing potential, that takes into account the likelihood and severity of the 
harms, along with an indication of whether these harms are considered life threatening; and 
§ a summary description of the main social harms caused by the new psychoactive substance 
to individuals and society, along with an indication of whether these harms are considered 
severe. 
For all three elements — extent and patterns of use, health risks and social harm — the level of 
uncertainty in the assessment should be expressed. 
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